Skip Navigation

AIDSInfo-at-a-glance

Issue No. 13 | March 25, 2011
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

Study Reports High Rate of Selection for Lamivudine Mutations in HIV-Infected, Treatment-Naive Children at the Time of Virologic Failure

“We included all the human immunodeficiency virus (HIV) type 1-infected highly active antiretroviral therapy (HAART)-naive children who started an LPV/r-based regimen between 2000 and 2009 at the Necker Hospital (Paris, France). Virologic failure (VF) was defined as an HIV-RNA ≥50 copies/mL. Resistance genotypic test was performed in case of VF. …

“HAART included LPV/r and 2 nucleoside reverse-transcriptase inhibitors, mainly lamivudine (3TC), zidovudine, and/or abacavir. … Less than 50 copies/mL of HIV RNA was observed in 46%, 67%, and 70% of the children at months 6, 9, and 12, respectively. In all, 20 children (46.5%) experienced a VF. The risk factors of primary VF were a young age and a low socioeconomic status. The genotypic resistance test, performed for 18 of 20 children with VF, revealed 1 LPV/r-resistant virus and protease inhibitor-related major mutations without LPV/r resistance in 2 other children. Of the 18 children with VF, 15 received a 3TC-based HAART: 12 of 15 (80%) harbored a 3TC-resistant virus. No virus resistant to zidovudine or abacavir was found. …

“In all, 70% of HAART-naive children had virologic success at month 12. The selection of LPV-resistant strains was a rare event. A high rate of selection of 3TC-mutations strengthens the recommendation to prefer a first-line 3TC-sparing regimen, particularly for children with risk factors of poor adherence.”

More information is available:

AIDSinfo is now on Facebook!

AIDSinfo is pleased to expand its social media presence by releasing a Facebook page.

The AIDSinfo Facebook page is designed to keep you informed by posting:

  • Announcements of newly released AIDSinfo content, such as revised HHS HIV treatment guidelines, HIV/AIDS awareness day specialty pages, and mobile applications
  • Links to HIV/AIDS-related consumer fact sheets developed by AIDSinfo health information specialists based on information from the HIV treatment guidelines and other expert sources
  • Breaking HIV/AIDS news and press releases on HIV/AIDS treatment and research
  • Information from other government agencies involved in HIV/AIDS treatment and research

The page is also a great way to provide feedback on AIDSinfo resources.

Connect with AIDSinfo on Facebook.

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Unsubscribe | Contact Us
Left footer corner image Left footer corner image